Coherus BioSciences, Inc. (CHRS): Price and Financial Metrics

Coherus BioSciences, Inc. (CHRS)

Today's Latest Price: $19.06 USD

0.17 (0.90%)

Updated Jan 29 11:34am

Add CHRS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 339 in Biotech

See all "A" rated Strong Buy stocks

CHRS Stock Summary

  • Coherus BioSciences Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 88.65% of US listed stocks.
  • CHRS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 0.51% of US stocks.
  • As for revenue growth, note that CHRS's revenue has grown 525.95% over the past 12 months; that beats the revenue growth of 98.68% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Coherus BioSciences Inc, a group of peers worth examining would be LXRX, SMSI, CPRX, MCHX, and ACMR.
  • Visit CHRS's SEC page to see the company's official filings. To visit the company's web site, go to
CHRS Daily Price Range
CHRS 52-Week Price Range

CHRS Stock Price Chart More Charts

CHRS Price/Volume Stats

Current price $19.06 52-week high $23.91
Prev. close $18.89 52-week low $12.60
Day low $18.62 Volume 155,552
Day high $19.21 Avg. volume 1,026,800
50-day MA $18.44 Dividend yield N/A
200-day MA $18.82 Market Cap 1.34B

Coherus BioSciences, Inc. (CHRS) Company Bio

Coherus Biosciences is a pure-play biosimilar platform company that develops and commercializes high-quality therapeutics for major regulated markets. The company was founded in 2010 and is based in Redwood City, California.

CHRS Latest News Stream

Event/Time News Detail
Loading, please wait...

CHRS Latest Social Stream

Loading social stream, please wait...

View Full CHRS Social Stream

CHRS Price Returns

1-mo 8.67%
3-mo 9.73%
6-mo -4.80%
1-year 50.20%
3-year -31.32%
5-year -15.06%
YTD 5.86%
2019 98.95%
2018 2.84%
2017 -68.74%
2016 22.60%
2015 40.69%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0905 seconds.